TG Therapeutics (NASDAQ:TGTX) perks up 2% premarket on light volume on the heels of results from a Phase 2 clinical trial evaluating ublituximab in patients with relapsing forms of multiple sclerosis (MS). The data were published in the Multiple Sclerosis Journal.
The responder rate was 100% in 48 patients and the annualized relapse rate at week 48 was 0.07 (average follow-up of ~47 weeks).
At weeks 24 and 48, no patient had new or
persisting gadolinium-enhancing lesion on any brain MRI scan (100%
reduction from baseline; P=0.003).
Two Phase 3 studies are ongoing.
https://seekingalpha.com/news/3567609-tg-therapeutics-up-2-on-ublituximab-data-in-ms
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.